慢性心力衰竭患者血清可溶性细胞间黏附分子-1和半乳糖凝集素-3的表达及其临床意义

目的 分析慢性心力衰竭患者血清可溶性细胞间黏附分子-1(soluble intercellular adhesion molecule-1,sICAM-1)、半乳糖凝集素-3(galectin 3)的表达及其临床意义。 方法 选择2016年3月—2019年3月杭州市第一人民医院淳安分院收治的452例慢性心力衰竭患者,根据NYHA分级法将其分为NYHAⅡ级组(151例)、NYHAⅢ级组(164例)、NYHAⅣ级组(137例),根据随访3个月内是否发生主要不良心血管事件(MACE)分为MACE组及非MACE组,另选取同期在我院体检者73例作为对照组,分别测定并比较各组血清sICAM-1和galectin 3水平。 结果 慢性心力衰竭组血清sICAM-1水平为(771.08±186.54)μg/L、galectin 3水平为(21.26±4.35)ng/mL均明显高于对照组(均P<0.05)。NYHAⅣ级组和NYHAⅢ级组血清sICAM-1、galectin 3表达水平明显高于NYHAⅡ级组(均P<0.05),NYHAⅣ级组明显高于NYHAⅢ级组(P<0.05)。MACE组入院次日和出院当日血清sICAM-1、galectin 3表达水平明显高于非MACE组(P<0.05),非MACE组出院当日血清sICAM-1、galectin 3表达水平明显低于入院次日(P<0.05)。慢性心力衰竭患者血清sICAM-1与galectin 3呈显著正相关(r=0.671,P=0.004)。 结论 血清sICAM-1、galectin 3表达水平与慢性心力衰竭患者心功能及预后有关。 

Expression and clinical significance of serum soluble intercellular adhesion molecule-1 and galactosan-3 in patients with chronic heart failure

Objective To analyze the expression and clinical significance of serum soluble intercellular adhesion molecule-1(sICAM-1) and galectin-3 in patients with chronic heart failure. Methods A total of 452 patients of with chronic heart failure admitted to Chun'an Branch of the First People's Hospital of Hangzhou from March 2016 to March 2019 were divided into NYHA Ⅱ group(151 cases), NYHA Ⅲ group(164 cases), and NYHA Ⅳ group(137 cases) according to NYHA classification. According to the occurrence of major adverse cardiovascular events(MACE) during the follow-up period, the patients were divided into MACE group and non-MACE group, another 73 cases of physical examination in our hospital during the same period were selected as the control group. The serum levels of sICAM-1 and galectin-3 were measured. Results The expression levels of sICAM-1 in the chronic heart failure group was(771.08±186.54) μg/L and galectin-3 was(21.26±4.35) ng/mL, there were significantly higher than those in the control group(all P<0.05). The expression levels of sICAM-1 and galectin-3 in the NYHA grade Ⅳ and NYHA grade Ⅲ groups were significantly higher than those in the NYHA grade Ⅱ group(all P<0.05), and that in the NYHA grade Ⅳ group was significantly higher than that in the NYHA grade Ⅲ group(P<0.05). The expression levels of sICAM-1 and galectin-3 in the MACE group on the next day of admission and the day of discharge were significantly higher than those of the non-MACE group(P<0.05). The expression of sICAM-1 and Galectin-3 on the day of discharge in the non-MACE group was significantly lower than that on the day after admission(P<0.05). There was a significant positive correlation between sICAM-1 and galectin-3 in patients with chronic heart failure(r=0.671, P=0.004). Conclusion The expression of sICAM-1 and galectin-3 in serum is related to the cardiac function and prognosis in patients with chronic heart failure.